Evaluation of plasma catestatin levels in patient with coronary slow flow

Year 2019, , 522 - 528, 04.05.2019

Dursun Topal , Bedrettin Boyraz Alkame Akgümüş Tezcan Peker Mustafa Yılmaz Fahriye Vatansever Ağca Selçuk Kanat Ömür Aydın Burhan Aslan

https://doi.org/10.18621/eurj.372631

Cited By: 1

Abstract

Objectives: Coronary slow flow (CSF) is characterized by delayed opasification of the
coronary arteries in the absence of obstructive coronary disease. Catestatin
has several cardiovasculer actions, in addition to diminihed sympato-adrenal
flow. The study was to investigated associations between CSF and plasma
catestatin levels.

Method:. This study included 45
CSF patients (37 male, mean age 48 ± 9.5 years) and 30 control individuals (24
male, mean age 48.4 ± 9 years). Coronary
flow was quantified according to the TIMI (Thrombolysis in Myocardial Infarction)
frame count method for coronary arteries. Serum
catestatin levels taken from blood samples were measured by ELISA method. These parameters were compared between the groups.

Results: When
compared with to the control group the serum catestatin levels
was found higher in the CSF group. In addition to this, mean platelet volume
was also significantly higher in patients with
coronary slow flow.

Conclusions: Our study revealed that catestatin levels are increased in
patients with CSF. Coronary slow flow
that increased catecholaminergic sympathetic system activities seem to be among
the reasons of endothelial dysfunction. 

Keywords

catestatin, coronary slow flow, coronary artery disease

References

• [1] Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries --a new angiographic finding. Am Heart J 1972;84:66-71.
• [2] Lierde JV, Vrolix M, Sionis D, De Geest H, et al. Piessens J. Lack of evidence for small vessel disease in a patient with ‘slow dye progression’ in the coronary arteries. Cathet Cardiovasc Diagn 1991;23:117-20.
• [3] Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010;32: 278-87.
• [4] Mahapatra NR. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 2008;80:330-8.
• [5] Brunner F, Bras-Silva C, Cerdeira AS,Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006;111:508-31.
• [6] Luscher TF, Tanner FC. Endothelial regulation of vascular tone and growth. Am J Hypertens 1993;6(7 Pt 2):283-93.
• [7] Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonism: roles in cardiovascular health and disease. Am Heart J 1995;130(3 Pt 1):601-10.
• [8] Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-33.
• [9] Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, et al. The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008;149:4780-93.
• [10] Liu L, Ding W, Li R, Ye X, Zhao J, Jiang J, et al. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides 2013;46:20-5.
• [11] Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am SocEchocardiogr 1989;2:358-67.
• [12] Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
• [13] Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, et al. Concentration of circulating plasma endothelin in patients with angına and normal coronary angiograms. Br Heart J 1995;74:620-4.
• [14] Kaski JC, Cox ID, Crook JR, Salomone OA, Fredericks S, Hann C, et al. Differential plasma endothelin concentrations in subgroups of patients with angına and angiographically normal coronary arteries: Coronary artery Disease Research Group. Am Heart J 1998;136:412-7.
• [15] Taupenot L, Harper KL, O’Connor DT. Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med 2003;348:1134-49.
• [16] Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007;64:2863-86.
• [17] Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
• [18] Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction. PLoS One 2015;10:e0122993.
• [19] Penna C, Alloatti G, Gallo PM, Cerra MC, Levi R, Tullio F, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 2010;30:1171-9.
• [20] Yazıcı M, Balcı B, Demircan S, Yeşildağ O, Sağkan O, Şahin M, et al. [Relationship between plasma endothelin-1 levels and corrected TIMI frame count in patients with slow coronary artery flow]. Türk Kardiyoloji Dern Arş 2002;30:466-72. [Article in Turkish]
• [21] Yazıcı M, Demircan S, Durna K, Şahin M. The role of adrenergic activity in slow coronary flow its relationship to TIMI frame count. Angiology 2007;58:393-400.
• [22] Nurkalem Z, Alper AT, Orhan AL, Zencirci AE, Sari I, Erer B, et al. Mean platelet volume in patients with slow coronary flow and its relationship with clinical presentation. Turk Kardiyol Dern Ars 2008;36:363-7.